Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MT-CO2 | P00403 | 6/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | GFER | P55789 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485977 | 1.00 | ALDH1A1 (0.58) | ALDH1A1KDM4ELMNAMT-CO2ALOX5 | |
| SCHEMBL28243691 | 1.00 | ALDH1A1 (0.58) | ALDH1A1KDM4ELMNAMT-CO2ALOX5 | |
| SCHEMBL16566170 | 0.90 | ALDH1A1 (0.50) | ALDH1A1KDM4ELMNAMAPTGAA | |
| SCHEMBL822035 | 0.87 | ALDH1A1 (0.49) | ALDH1A1MAPTGAAGFERSMN1; SMN2 | |
| SCHEMBL13057572 | 0.84 | GAA (0.52) | ALDH1A1KDM4ELMNAMT-CO2ALOX5 | |
| SCHEMBL14821834 | 0.83 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNAMAPTGAA | |
| SCHEMBL16566172 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KDM4ELMNAMAPTGAA | |
| SCHEMBL20375597 | 0.82 | MAPT (0.42) | ALDH1A1LMNAMAPTTDP1SMN1; SMN2 | |
| SCHEMBL16450893 | 0.81 | HSP90AA1 (0.59) | ALDH1A1LMNAMAPTGAASMN1; SMN2 | |
| SCHEMBL13057567 | 0.81 | ALDH1A1 (0.51) | ALDH1A1MT-CO2ALOX5MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0871439-A4 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 1999-07-21 | — | — | EP | claimed |
| EP-0871439-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-10-21 | — | — | EP | claimed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | claimed |
| US-20240032209-A1 | MALEIMIDE RESIN COMPOSITION, PREPREG, RESIN FILM, LAMINATED BOARD, PRINTED WIRING BOARD, AND SEMICONDUCTOR PACKAGE | RESONAC CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240032209-A1 | MALEIMIDE RESIN COMPOSITION, PREPREG, RESIN FILM, LAMINATED BOARD, PRINTED WIRING BOARD, AND SEMICONDUCTOR PACKAGE | RESONAC CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| EP-2558127-B1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | SEAGEN INC (US) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020245283-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC THERAPEUTICS SA (CH) | 2020-12-10 | — | — | WO | disclosed |
| CN-108587927-B | (S)-selectivity organism catalyst | 中山大学 | 2019-08-09 | — | — | CN | disclosed |
| CN-108587927-A | (S)-selectivity organism catalyst | 中山大学 | 2018-09-28 | — | — | CN | disclosed |
| EP-3309162-A1 | TARGETED CONJUGATES OF PYRROLOBENZODIAZEPINES | Seattle Genetics, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-1959019-A1 | Method for enzymatic reduction of alkene derivates | BASF SE (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008058951-A1 | PROCESS FOR ENZYMATIC REDUCTION OF ALKENE DERIVATIVES | BASF SE (DE) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008058951-A1 | PROCESS FOR ENZYMATIC REDUCTION OF ALKENE DERIVATIVES | BASF SE (DE) | 2008-05-22 | — | — | WO | disclosed |
| US-20070173636-A1 | Method for preparing polyfunctionalized peptides and/or proteins via native chemical ligation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-07-26 | — | — | US | disclosed |
| US-7232805-B2 | Cobalamin conjugates for anti-tumor therapy | INFLABLOC PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7160856-B2 | α-O-linked glycoconjugates, methods of preparation and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-01-09 | — | — | US | disclosed |
| US-4847285-A | 1-substituted phenyl-3-substituted methyl-pyrrolidine-2,5-diones and plant fungicide compositions containing same | THE DOW CHEMICAL COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0173284-A1 | Substituted 1-phenyl-3-methyl-pyrrolidindiones, their manufacture and use as fungicides | THE DOW CHEMICAL COMPANY (US) | 1986-03-05 | — | — | EP | disclosed |
| US-4204970-A | Lubricant compositions containing alkylated aromatic amino acid antioxidants | STANDARD OIL COMPANY (INDIANA) (US) | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173636-A1 | Method for preparing polyfunctionalized peptides and/or proteins via native chemical ligation | TXNL1, NGLY1, RXFP1 | ALDH1A1 3808/4885KDM4E 2759/4885LMNA 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.